《Clinica Chimica Acta,6月6日,Comparative analysis of laboratory indexes of severe and non-severe patients infected with COVID-19》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-06-06
  • Comparative analysis of laboratory indexes of severe and non-severe patients infected with COVID-19

    Author links open overlay panelJingfengBaoa1ChenxiLia1KaiZhangb1HaiquanKangcWensenChendeBingGuac

    Show more

    https://doi.org/10.1016/j.cca.2020.06.009

    Abstract

    Background

    The pandemic coronavirus disease 2019 (COVID-19) has threaten the global health. The characteristics of laboratory findings of coronavirus are of great significance for clinical diagnosis and treatment. We found indicators that may most effectively predict a non-severe COVID-19 patient develop into a severe patient.

    Methods

    We conducted a meta-analysis to compare the laboratory findings of severe patients with non-severe patients with COVID-19 from searched articles.

  • 原文来源:https://www.sciencedirect.com/science/article/abs/pii/S0009898120302734
相关报告
  • 《Nature,12月29日,In-depth blood proteome profiling analysis revealed distinct functional characteristics of plasma proteins between severe and non-severe COVID-19 patients》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2021-02-03
    • In-depth blood proteome profiling analysis revealed distinct functional characteristics of plasma proteins between severe and non-severe COVID-19 patients Joonho Park, Hyeyoon Kim, So Yeon Kim, Yeonjae Kim, Jee-Soo Lee, Kisoon Dan, Moon-Woo Seong & Dohyun Han Scientific Reports volume 10, Article number: 22418 (2020) Abstract The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over forty million patients worldwide. Although most coronavirus disease 2019 (COVID-19) patients have a good prognosis, some develop severe illness. Markers that define disease severity or predict clinical outcome need to be urgently developed as the mortality rate in critical cases is approximately 61.5%. In the present study, we performed in-depth proteome profiling of undepleted plasma from eight COVID-19 patients. Quantitative proteomic analysis using the BoxCar method revealed that 91 out of 1222 quantified proteins were differentially expressed depending on the severity of COVID-19. Importantly, we found 76 proteins, previously not reported, which could be novel prognostic biomarker candidates. Our plasma proteome signatures captured the host response to SARS-CoV-2 infection, thereby highlighting the role of neutrophil activation, complement activation, platelet function, and T cell suppression as well as proinflammatory factors upstream and downstream of interleukin-6, interleukin-1B, and tumor necrosis factor. Consequently, this study supports the development of blood biomarkers and potential therapeutic targets to aid clinical decision-making and subsequently improve prognosis of COVID-19.
  • 《MedRxiv,3月9日,Comparison of severe and non-severe COVID-19 pneumonia: review and meta-analysis》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-03-10
    • Comparison of severe and non-severe COVID-19 pneumonia: review and meta-analysis Weiping Ji, Jing Zhang, Gautam Bishnu, Xudong Du, Xinxin Chen, Hui Xu, Xiaoling Guo, Zhenzhai Cai, Xian Shen doi: https://doi.org/10.1101/2020.03.04.20030965 Abstract Objective: To compare the difference between severe and non-severe COVID-19 pneumonia and figure out the potential symptoms lead to severity. Methods: Articles from PubMed, Embase, Cochrane database, and google up-to 24 February 2020 were systematically reviewed. Eighteen Literatures were identified with cases of COVID-19 pneumonia. The extracted data includes clinical symptoms, age, gender, sample size and region et al were systematic reviewed and meta analyzed. Results: 14 eligible studies including 1,424 patients were analyzed. Symptoms like fever (89.2%), cough (67.2%), fatigue (43.6%) were common, dizziness, hemoptysis, abdominal pain and conjunctival congestion/conjunctivitis were rare. *注,本文为预印本论文手稿,是未经同行评审的初步报告,其观点仅供科研同行交流,并不是结论性内容,请使用者谨慎使用.